Prevention of apnea and bradycardia in low birthweight infants

D. C. Shannon, F. Gotay, I. M. Stein, M. C. Rogers, I. D. Todres, F. M. Moylan

Research output: Contribution to journalArticle

Abstract

The efficacy of theophylline in preventing severe apnea was evaluated in 17 low birthweight infants (mean weight, 1,400 gm). Apnea was detected and accurately quantified by 13 hour pneumogram recordings and correlated with serum theophylline levels. Nursing observations coupled with on line alarm systems detected only 39% of severe apneic episodes as compared to the pneumogram recording technique. Theophylline in six hourly oral doses (1.5 to 4.0 mg/kg) yielded two hour serum concentrations of 6.6 to 11.0 μg/ml which completely controlled apneic spells exceeding 20 seconds in duration and markedly reduced 10 to 19 second apneic episodes and any resultant bradycardia. At these serum levels, toxicity was not observed. Therapy with theophylline should be instituted at a dose of 2 to 3 mg/kg every six hours and the optimum therapeutic dose should be individualized as determined by objective quantitation of apnea and serum theophylline concentration.

Original languageEnglish (US)
Pages (from-to)589-594
Number of pages6
JournalPediatrics
Volume55
Issue number5
StatePublished - 1975
Externally publishedYes

Fingerprint

Apnea
Bradycardia
Theophylline
Serum
Online Systems
Nursing
Weights and Measures
Therapeutics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Shannon, D. C., Gotay, F., Stein, I. M., Rogers, M. C., Todres, I. D., & Moylan, F. M. (1975). Prevention of apnea and bradycardia in low birthweight infants. Pediatrics, 55(5), 589-594.

Prevention of apnea and bradycardia in low birthweight infants. / Shannon, D. C.; Gotay, F.; Stein, I. M.; Rogers, M. C.; Todres, I. D.; Moylan, F. M.

In: Pediatrics, Vol. 55, No. 5, 1975, p. 589-594.

Research output: Contribution to journalArticle

Shannon, DC, Gotay, F, Stein, IM, Rogers, MC, Todres, ID & Moylan, FM 1975, 'Prevention of apnea and bradycardia in low birthweight infants', Pediatrics, vol. 55, no. 5, pp. 589-594.
Shannon DC, Gotay F, Stein IM, Rogers MC, Todres ID, Moylan FM. Prevention of apnea and bradycardia in low birthweight infants. Pediatrics. 1975;55(5):589-594.
Shannon, D. C. ; Gotay, F. ; Stein, I. M. ; Rogers, M. C. ; Todres, I. D. ; Moylan, F. M. / Prevention of apnea and bradycardia in low birthweight infants. In: Pediatrics. 1975 ; Vol. 55, No. 5. pp. 589-594.
@article{adc7bbb6b8e04e038321fc8e236a3a54,
title = "Prevention of apnea and bradycardia in low birthweight infants",
abstract = "The efficacy of theophylline in preventing severe apnea was evaluated in 17 low birthweight infants (mean weight, 1,400 gm). Apnea was detected and accurately quantified by 13 hour pneumogram recordings and correlated with serum theophylline levels. Nursing observations coupled with on line alarm systems detected only 39{\%} of severe apneic episodes as compared to the pneumogram recording technique. Theophylline in six hourly oral doses (1.5 to 4.0 mg/kg) yielded two hour serum concentrations of 6.6 to 11.0 μg/ml which completely controlled apneic spells exceeding 20 seconds in duration and markedly reduced 10 to 19 second apneic episodes and any resultant bradycardia. At these serum levels, toxicity was not observed. Therapy with theophylline should be instituted at a dose of 2 to 3 mg/kg every six hours and the optimum therapeutic dose should be individualized as determined by objective quantitation of apnea and serum theophylline concentration.",
author = "Shannon, {D. C.} and F. Gotay and Stein, {I. M.} and Rogers, {M. C.} and Todres, {I. D.} and Moylan, {F. M.}",
year = "1975",
language = "English (US)",
volume = "55",
pages = "589--594",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "5",

}

TY - JOUR

T1 - Prevention of apnea and bradycardia in low birthweight infants

AU - Shannon, D. C.

AU - Gotay, F.

AU - Stein, I. M.

AU - Rogers, M. C.

AU - Todres, I. D.

AU - Moylan, F. M.

PY - 1975

Y1 - 1975

N2 - The efficacy of theophylline in preventing severe apnea was evaluated in 17 low birthweight infants (mean weight, 1,400 gm). Apnea was detected and accurately quantified by 13 hour pneumogram recordings and correlated with serum theophylline levels. Nursing observations coupled with on line alarm systems detected only 39% of severe apneic episodes as compared to the pneumogram recording technique. Theophylline in six hourly oral doses (1.5 to 4.0 mg/kg) yielded two hour serum concentrations of 6.6 to 11.0 μg/ml which completely controlled apneic spells exceeding 20 seconds in duration and markedly reduced 10 to 19 second apneic episodes and any resultant bradycardia. At these serum levels, toxicity was not observed. Therapy with theophylline should be instituted at a dose of 2 to 3 mg/kg every six hours and the optimum therapeutic dose should be individualized as determined by objective quantitation of apnea and serum theophylline concentration.

AB - The efficacy of theophylline in preventing severe apnea was evaluated in 17 low birthweight infants (mean weight, 1,400 gm). Apnea was detected and accurately quantified by 13 hour pneumogram recordings and correlated with serum theophylline levels. Nursing observations coupled with on line alarm systems detected only 39% of severe apneic episodes as compared to the pneumogram recording technique. Theophylline in six hourly oral doses (1.5 to 4.0 mg/kg) yielded two hour serum concentrations of 6.6 to 11.0 μg/ml which completely controlled apneic spells exceeding 20 seconds in duration and markedly reduced 10 to 19 second apneic episodes and any resultant bradycardia. At these serum levels, toxicity was not observed. Therapy with theophylline should be instituted at a dose of 2 to 3 mg/kg every six hours and the optimum therapeutic dose should be individualized as determined by objective quantitation of apnea and serum theophylline concentration.

UR - http://www.scopus.com/inward/record.url?scp=0016715437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016715437&partnerID=8YFLogxK

M3 - Article

C2 - 236535

AN - SCOPUS:0016715437

VL - 55

SP - 589

EP - 594

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 5

ER -